Exin Therapeutics vs Fluor Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI neurotherapeutics discovery platform for epilepsy/autism/Parkinson's with multimodal neural AI; animal lab + proof-of-concept + 2 patents in 1.5 months; $25M Philippines lab investment competing with Recursion for AI-driven CNS gene therapy.
About
Exin Therapeutics is a San Francisco-based AI-powered neurotherapeutics drug discovery company — pioneering genetic therapies that target neural activity to treat epilepsy, autism spectrum disorder symptoms, Parkinson's disease, and other neurological conditions using a multimodal AI platform that predicts therapeutic candidate potential across multiple neural disorders simultaneously. Using neural activity recordings, behavioral assays, and transcriptomics data as inputs, Exin's AI models identify genetic intervention targets and predict therapeutic outcomes before entering animal studies — compressing the target identification timeline that traditional neuroscience drug discovery requires. The company established an animal research facility, obtained proof-of-concept results in mice, and filed two provisional patents within 1.5 months of San Francisco operations, and is investing approximately $25 million to build the Philippines' first neurotherapeutics laboratory.
Irving TX global EPC contractor (NYSE: FLR) at $16.3B 2024 revenue with $17.7B backlog; new CEO Jim Breuer May 2025 growing data center/semiconductor segment from BHP Olympic Dam to CHIPS Act fabs competing with Bechtel and AECOM.
About
Fluor Corporation is an Irving, Texas-based engineering, procurement, and construction (EPC) company — publicly traded on the New York Stock Exchange (NYSE: FLR) — providing global energy, chemicals, infrastructure, government, and advanced technology clients with EPC project delivery services across the full capital project lifecycle from feasibility through commissioning and maintenance. In 2024, Fluor reported $16.3 billion in revenue (Fortune 500 #265) with $9.5 billion in new awards and an $17.7 billion ending backlog, demonstrating pipeline growth driven by the AI data center construction surge, semiconductor manufacturing expansion (CHIPS Act-funded fabs), and life sciences facility build-out. In May 2025, Jim Breuer was named CEO, succeeding David Constable who became Executive Chairman. Founded in 1912 (113-year operating history), Fluor operates through Urban Solutions (infrastructure, manufacturing, life sciences), Mission Solutions (government), and Energy Solutions (oil, gas, chemicals, renewables) segments.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.